Literature DB >> 22189117

High proportion of fluoroquinolone-resistant Mycobacterium tuberculosis isolates with novel gyrase polymorphisms and a gyrA region associated with fluoroquinolone susceptibility.

Rose Devasia1, Amondrea Blackman, Svetlana Eden, Haijing Li, Fernanda Maruri, Ayumi Shintani, Charles Alexander, Anne Kaiga, Charles W Stratton, Jon Warkentin, Yi-Wei Tang, Timothy R Sterling.   

Abstract

Fluoroquinolone resistance in Mycobacterium tuberculosis can be conferred by mutations in gyrA or gyrB. The prevalence of resistance mutations outside the quinolone resistance-determining region (QRDR) of gyrA or gyrB is unclear, since such regions are rarely sequenced. M. tuberculosis isolates from 1,111 patients with newly diagnosed culture-confirmed tuberculosis diagnosed in Tennessee from 2002 to 2009 were screened for phenotypic ofloxacin resistance (>2 μg/ml). For each resistant isolate, two ofloxacin-susceptible isolates were selected: one with antecedent fluoroquinolone exposure and one without. The complete gyrA and gyrB genes were sequenced and compared with M. tuberculosis H37Rv. Of 25 ofloxacin-resistant isolates, 11 (44%) did not have previously reported resistance mutations. Of these, 10 had novel polymorphisms: 3 in the QRDR of gyrA, 1 in the QRDR of gyrB, and 6 outside the QRDR of gyrA or gyrB; 1 did not have any gyrase polymorphisms. Polymorphisms in gyrA codons 1 to 73 were more common in fluoroquinolone-susceptible than in fluoroquinolone-resistant strains (20% versus 0%; P = 0.016). In summary, almost half of fluoroquinolone-resistant M. tuberculosis isolates did not have previously described resistance mutations, which has implications for genotypic diagnostic tests.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22189117      PMCID: PMC3318526          DOI: 10.1128/JCM.05286-11

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  33 in total

1.  American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis.

Authors:  Henry M Blumberg; William J Burman; Richard E Chaisson; Charles L Daley; Sue C Etkind; Lloyd N Friedman; Paula Fujiwara; Malgosia Grzemska; Philip C Hopewell; Michael D Iseman; Robert M Jasmer; Venkatarama Koppaka; Richard I Menzies; Richard J O'Brien; Randall R Reves; Lee B Reichman; Patricia M Simone; Jeffrey R Starke; Andrew A Vernon
Journal:  Am J Respir Crit Care Med       Date:  2003-02-15       Impact factor: 21.405

2.  Genotypic and phenotypic resistance of Mycobacterium tuberculosis to rifamycins and fluoroquinolones.

Authors:  W W Yew; E Chan; C Y Chan; A F Cheng
Journal:  Int J Tuberc Lung Dis       Date:  2002-10       Impact factor: 2.373

3.  Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations.

Authors:  H E Takiff; L Salazar; C Guerrero; W Philipp; W M Huang; B Kreiswirth; S T Cole; W R Jacobs; A Telenti
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

4.  Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin.

Authors:  E Cambau; W Sougakoff; M Besson; C Truffot-Pernot; J Grosset; V Jarlier
Journal:  J Infect Dis       Date:  1994-08       Impact factor: 5.226

5.  Rv2686c-Rv2687c-Rv2688c, an ABC fluoroquinolone efflux pump in Mycobacterium tuberculosis.

Authors:  Maria Rosalia Pasca; Paola Guglierame; Fabio Arcesi; Marco Bellinzoni; Edda De Rossi; Giovanna Riccardi
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

6.  Sequences of conserved region in the A subunit of DNA gyrase from nine species of the genus Mycobacterium: phylogenetic analysis and implication for intrinsic susceptibility to quinolones.

Authors:  I Guillemin; E Cambau; V Jarlier
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

7.  Emergence of fluoroquinolone-resistant tuberculosis in New York City.

Authors:  E A Sullivan; B N Kreiswirth; L Palumbo; V Kapur; J M Musser; A Ebrahimzadeh; T R Frieden
Journal:  Lancet       Date:  1995-05-06       Impact factor: 79.321

8.  Efflux pump of the proton antiporter family confers low-level fluoroquinolone resistance in Mycobacterium smegmatis.

Authors:  H E Takiff; M Cimino; M C Musso; T Weisbrod; R Martinez; M B Delgado; L Salazar; B R Bloom; W R Jacobs
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

9.  Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence.

Authors:  S T Cole; R Brosch; J Parkhill; T Garnier; C Churcher; D Harris; S V Gordon; K Eiglmeier; S Gas; C E Barry; F Tekaia; K Badcock; D Basham; D Brown; T Chillingworth; R Connor; R Davies; K Devlin; T Feltwell; S Gentles; N Hamlin; S Holroyd; T Hornsby; K Jagels; A Krogh; J McLean; S Moule; L Murphy; K Oliver; J Osborne; M A Quail; M A Rajandream; J Rogers; S Rutter; K Seeger; J Skelton; R Squares; S Squares; J E Sulston; K Taylor; S Whitehead; B G Barrell
Journal:  Nature       Date:  1998-06-11       Impact factor: 49.962

10.  Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity.

Authors:  Alexandra Aubry; Xiao-Su Pan; L Mark Fisher; Vincent Jarlier; Emmanuelle Cambau
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

View more
  19 in total

1.  High proportion of heteroresistance in gyrA and gyrB in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates.

Authors:  Brandon Eilertson; Fernanda Maruri; Amondrea Blackman; Miguel Herrera; David C Samuels; Timothy R Sterling
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

2.  Fluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to older- versus newer-generation fluoroquinolones.

Authors:  Yuri F van der Heijden; Fernanda Maruri; Amondrea Blackman; Ed Mitchel; Aihua Bian; Ayumi K Shintani; Svetlana Eden; Jon V Warkentin; Timothy R Sterling
Journal:  Int J Antimicrob Agents       Date:  2013-06-24       Impact factor: 5.283

3.  De Novo Emergence of Genetically Resistant Mutants of Mycobacterium tuberculosis from the Persistence Phase Cells Formed against Antituberculosis Drugs In Vitro.

Authors:  Jees Sebastian; Sharmada Swaminath; Rashmi Ravindran Nair; Kishor Jakkala; Atul Pradhan; Parthasarathi Ajitkumar
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

4.  Highly multiplexed rapid DNA detection with single-nucleotide specificity via convective PCR in a portable device.

Authors:  Dmitriy Khodakov; Jiaming Li; Jinny X Zhang; David Yu Zhang
Journal:  Nat Biomed Eng       Date:  2021-07-01       Impact factor: 25.671

5.  Mutations in gyrA and gyrB among Fluoroquinolone- and Multidrug-Resistant Mycobacterium tuberculosis Isolates.

Authors:  Jung-Yien Chien; Wei-Yih Chiu; Shun-Tien Chien; Chia-Jung Chiang; Chong-Jen Yu; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

6.  Mutations in gyrA and gyrB in Moxifloxacin-Resistant Mycobacterium avium Complex and Mycobacterium abscessus Complex Clinical Isolates.

Authors:  Su-Young Kim; Byung Woo Jhun; Seong Mi Moon; Sun Hye Shin; Kyeongman Jeon; O Jung Kwon; In Young Yoo; Hee Jae Huh; Chang-Seok Ki; Nam Yong Lee; Sung Jae Shin; Charles L Daley; Gee Young Suh; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

7.  Prevalence of gyrA and B gene mutations in fluoroquinolone-resistant and -sensitive clinical isolates of Mycobacterium tuberculosis and their relationship with MIC of ofloxacin.

Authors:  Pooja Singh; Amita Jain; Pratima Dixit; Shantanu Prakash; Indu Jaiswal; Vimala Venkatesh; Mastan Singh
Journal:  J Antibiot (Tokyo)       Date:  2014-07-23       Impact factor: 2.649

8.  A novel resistance mutation in eccC5 of the ESX-5 secretion system confers ofloxacin resistance in Mycobacterium tuberculosis.

Authors:  Brandon Eilertson; Fernanda Maruri; Amondrea Blackman; Yan Guo; Miguel Herrera; Yuri van der Heijden; Yu Shyr; Timothy R Sterling
Journal:  J Antimicrob Chemother       Date:  2016-06-03       Impact factor: 5.790

9.  Sequence Analysis of Fluoroquinolone Resistance-Associated Genes gyrA and gyrB in Clinical Mycobacterium tuberculosis Isolates from Patients Suspected of Having Multidrug-Resistant Tuberculosis in New Delhi, India.

Authors:  Ritu Singhal; Paul R Reynolds; Jamie L Marola; L Elaine Epperson; Jyoti Arora; Rohit Sarin; Vithal Prasad Myneedu; Michael Strong; Max Salfinger
Journal:  J Clin Microbiol       Date:  2016-06-22       Impact factor: 5.948

10.  Role of gyrB Mutations in Pre-extensively and Extensively Drug-Resistant Tuberculosis in Thai Clinical Isolates.

Authors:  Areeya Disratthakit; Therdsak Prammananan; Chanwit Tribuddharat; Iyarit Thaipisuttikul; Norio Doi; Manoon Leechawengwongs; Angkana Chaiprasert
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.